secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001104659-23-115226
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports Q3 net loss of $113.8M; BLA for lifileucel on track with PDUFA Feb 24, 2024
--------------------------------------------------------------------------------

- Net loss of $113.8M ($0.46/share) vs $99.6M ($0.63/share) in Q3 2022; revenue of $0.5M from Proleukin acquisition.
- FDA Priority Review of lifileucel BLA on track; PDUFA date Feb 24, 2024; pre-approval inspections completed.
- Onboarding completed at ~30 ATCs for potential U.S. commercial launch of lifileucel as first approved TIL therapy.
- Cash position of $427.8M at Sept 30, 2023; raised ~$203.2M in Q3 from offerings; cash expected to fund operations into 2025.
- Regulatory submissions for lifileucel in Europe and Canada planned for 2024; IOV-LUN-202 NSCLC trial enrollment on track for completion H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923115226/0001104659-23-115226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923115226/tm2330006d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer